A retrospective chart review compared the difference in outcomes between Black patients and White patients with advanced RCC for 3 first-line therapies.
GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback